FOLFIRINOX chemo after surgery for pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This Phase 2 study tests whether FOLFIRINOX given after pancreatic surgery can lower the chance the cancer comes back. It focuses on people with pancreatic ductal adenocarcinoma who had their tumor completely removed and have no spread to distant organs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic adenocarcinoma confirmed by pathology, and it has not spread to distant sites
- You had “radical” (curative) surgery for pancreatic cancer
- You have not had chemotherapy before this study
- You can use effective birth control during the study (if age-eligible), and you are not pregnant or breastfeeding
- Your blood counts and organs (liver, kidneys) are strong enough for chemotherapy
- You can tolerate chemo: no recent serious heart problems, no known allergies to the study drugs, and you don’t have certain nerve or bowel issues
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (mFOLFIRINOX) and radiation therapy for people with advanced pancreatic cancer that has stopped responding to chemotherapy and whose CA19-9 tumor marker levels are normal. The goal is to see if this approach can help when standard treatments are no longer working.
This trial tests a new drug (NP137) combined with the chemotherapy FOLFIRINOX before and after surgery for people with pancreatic cancer that can be removed. The goal is to see if this combination helps prevent the cancer from coming back.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) given before and after surgery for people with pancreatic cancer that is at high risk of coming back but can still be surgically removed. The goal is to see if this treatment helps improve outcomes.
This trial compares giving chemotherapy with FOLFIRINOX before and after surgery versus giving it mainly after surgery for people with resectable pancreatic duct cancer. It aims to improve outcomes by timing the treatment around the operation.
This study follows people with pancreatic cancer who are receiving a chemotherapy combination called FOLFIRINOX after surgery. The goal is to see how well the treatment works over time and how it affects long-term survival and cancer recurrence.
This trial tests a stronger version of FOLFIRINOX chemotherapy for people with pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body. It aims to see if the new dosing schedule works better and is safe.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.